Comparative analysis of COVID-19-related mortality risk in chronic lower respiratory disease and interstitial lung disease
Keywords:
COPD, ILD, COVID-19, mortality rateReferences
Calver JF, Fabbri L, May J, Jenkins RG. COVID-19 in Patients with Chronic Lung Disease. Clin Chest Med 2023; 44: 385-393.
Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research. Multiple cause of death, 2018–2021. https://wonder.cdc.gov/mcd.html. .
Jeganathan N, Cleland D, Sathananthan M. The association of lung cancer with pulmonary fibrosis. ERJ Open Res 2022; 8.
Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021; 9: 909-923.
Drake TM, Docherty AB, Harrison EM, et.al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 2020; 202: 1656-1665.
Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020; 8: 436-438.
Sanchez-Ramirez DC, Mackey D. Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis. Respir Med 2020; 171: 106096.
Vasquez Reyes M. The Disproportional Impact of COVID-19 on African Americans. Health Hum Rights 2020; 22: 299-307.
Jeganathan N, Sathananthan M. Urban-Rural Differences in Idiopathic Pulmonary Fibrosis-Related Mortality Rates in the United States. Chest 2024; 165: 924-928.
Baughman RP, Lower EE. COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2021; 38: e2021029.
Baughman RP, Lower EE, Buchanan M, et al. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37: e2020009.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 George W. Hafzalla, Hyein Ji, Niranjan Jeganathan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
